# Clinical Trial Landscape: 12_elderly_cll_poor_performance

*Generated: 2026-01-05 07:00:17*

## Summary

- **Total Trials**: 65
- **Flagged for Review**: 0
- **Search Terms Used**: 12

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 2 | 22 | ██████ 33.8% |
| Phase 1 | 15 | ████ 23.1% |
| Unknown | 9 | ██ 13.8% |
| Phase 1/Phase 2 | 7 | ██ 10.8% |
| Not Applicable | 4 | █ 6.2% |
| Phase 3 | 4 | █ 6.2% |
| Early Phase 1 | 3 |  4.6% |
| Phase 4 | 1 |  1.5% |

## Status Distribution

- **Recruiting**: 62 (95.4%)
- **Enrolling by invitation**: 2 (3.1%)
- **Not yet recruiting**: 1 (1.5%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| City of Hope Medical Center | 6 |
| National Heart, Lung, and Blood Institute (NHLBI) | 3 |
| National Cancer Institute (NCI) | 3 |
| Dana-Farber Cancer Institute | 2 |
| Mayo Clinic | 2 |
| Fred Hutchinson Cancer Center | 2 |
| Massachusetts General Hospital | 2 |
| Nurix Therapeutics, Inc. | 2 |
| BeOne Medicines | 2 |
| Loxo Oncology, Inc. | 2 |
| Texas A&M University | 2 |
| Masonic Cancer Center, University of Minnesota | 1 |
| Cancer Support Community, Research and Training In | 1 |
| M.D. Anderson Cancer Center | 1 |
| Marlise Luskin, MD | 1 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Biospecimen Collection | 16 |
| Computed Tomography | 13 |
| Bone Marrow Biopsy | 12 |
| Cyclophosphamide | 11 |
| Fludarabine | 9 |
| Bone Marrow Aspiration | 7 |
| Obinutuzumab | 6 |
| Positron Emission Tomography | 6 |
| Questionnaire Administration | 6 |
| Multigated Acquisition Scan | 6 |
| Echocardiography | 5 |
| Blinatumomab | 4 |
| Venetoclax | 4 |
| Biopsy | 4 |
| Zanubrutinib | 4 |
| Acalabrutinib | 3 |
| Allogeneic Hematopoietic Stem Cell Transplantation | 3 |
| Mycophenolate Mofetil | 3 |
| Echocardiography Test | 3 |
| Pirtobrutinib | 3 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 65 |
| Canada | 9 |
| France | 8 |
| Spain | 8 |
| Australia | 7 |
| Germany | 7 |
| Italy | 7 |
| Japan | 6 |
| United Kingdom | 6 |
| South Korea | 5 |
| Turkey (Türkiye) | 5 |
| China | 3 |
| Brazil | 3 |
| Poland | 3 |
| Belgium | 3 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| TP53 deletion | manual | 1.0 |
| TP53deletion | manual | 0.9 |
| TP53-deletion | manual | 0.9 |
| IGHV unmutated | manual | 1.0 |
| IGHVunmutated | manual | 0.9 |
| IGHV-unmutated | manual | 0.9 |
| chronic lymphocytic leukemia | manual | 1.0 |
| TP53 deletion chronic lymphocytic leukemia | manual | 1.0 |
| IGHV unmutated chronic lymphocytic leukemia | manual | 1.0 |
| TP53 deletion CLL | llm | 0.9 |
| CLL | llm | 0.8 |
| del(17p) | llm | 0.9 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT07061951](https://clinicaltrials.gov/study/NCT07061951) | Phase 2 | Recruiting | National Cancer Inst... | A Phase 2 Pilot Study of Mirdametin... |
| [NCT06863402](https://clinicaltrials.gov/study/NCT06863402) | Phase 2 | Recruiting | Roswell Park Cancer ... | Nemtabrutinib and Pembrolizumab in ... |
| [NCT06859008](https://clinicaltrials.gov/study/NCT06859008) | Phase 1 | Recruiting | City of Hope Medical... | Feasibility of Treating Relapsed/Re... |
| [NCT07166419](https://clinicaltrials.gov/study/NCT07166419) | Phase 1 | Recruiting | Ohio State Universit... | Phase I Clinical Trial of Caring Cr... |
| [NCT07218510](https://clinicaltrials.gov/study/NCT07218510) | Phase 2 | Recruiting | City of Hope Medical... | A Phase 2 Study of Venetoclax + Obi... |
| [NCT06973187](https://clinicaltrials.gov/study/NCT06973187) | Phase 3 | Recruiting | BeOne Medicines | A Phase 3, Open-Label, Randomized S... |
| [NCT06735664](https://clinicaltrials.gov/study/NCT06735664) | Phase 1 | Recruiting | City of Hope Medical... | A Phase I Study of Covalent BTK Inh... |
| [NCT06916767](https://clinicaltrials.gov/study/NCT06916767) | Phase 1 | Recruiting | Paolo Caimi, MD | Phase 1 Study of BAFF CAR-T Cells (... |
| [NCT06735690](https://clinicaltrials.gov/study/NCT06735690) | Early Phase 1 | Recruiting | City of Hope Medical... | Pilot/Feasibility Study of CMV-Spec... |
| [NCT06839053](https://clinicaltrials.gov/study/NCT06839053) | Phase 2 | Recruiting | Fred Hutchinson Canc... | Escalated Inpatient Ramp-Up of Sonr... |
| [NCT06533579](https://clinicaltrials.gov/study/NCT06533579) | Phase 1/Phase 2 | Recruiting | Vironexis Biotherape... | A Phase 1/2 Safety, Dose-finding, a... |
| [NCT06757647](https://clinicaltrials.gov/study/NCT06757647) | Phase 2 | Recruiting | Seema Bhat | Prospective Phase 2 Study of the Ef... |
| [NCT06849713](https://clinicaltrials.gov/study/NCT06849713) | Phase 2 | Recruiting | Massachusetts Genera... | A Phase 2 Study of Zanubrutinib, Ob... |
| [NCT06993012](https://clinicaltrials.gov/study/NCT06993012) | Not Applicable | Enrolling by invitation | Texas A&M University | An Integrative, Digital Health Appr... |
| [NCT06815003](https://clinicaltrials.gov/study/NCT06815003) | Phase 2 | Recruiting | City of Hope Medical... | Phase-2 Study of Vedolizumab Plus P... |
| [NCT06839456](https://clinicaltrials.gov/study/NCT06839456) | Phase 1/Phase 2 | Recruiting | Children's Hospital ... | Phase 1/2 Study: CD45RA Depleted Pe... |
| [NCT06784167](https://clinicaltrials.gov/study/NCT06784167) | N/A | Recruiting | OHSU Knight Cancer I... | Vaccine Responses in Patient With M... |
| [NCT06636175](https://clinicaltrials.gov/study/NCT06636175) | Early Phase 1 | Recruiting | Washington Universit... | Early Phase I Evaluation of 64Cu-LL... |
| [NCT06680661](https://clinicaltrials.gov/study/NCT06680661) | Phase 2 | Recruiting | Leland Metheny | ABBA CORD: Double Umbilical Cord Bl... |
| [NCT06588478](https://clinicaltrials.gov/study/NCT06588478) | Phase 2 | Recruiting | Loxo Oncology, Inc. | A Phase 2, Open-Label, Randomized S... |
| [NCT06398457](https://clinicaltrials.gov/study/NCT06398457) | Early Phase 1 | Recruiting | Sidney Kimmel Compre... | A Pilot Study of Darzalex Faspro (D... |
| [NCT05899543](https://clinicaltrials.gov/study/NCT05899543) | N/A | Not yet recruiting | Power Life Sciences ... | Exploring Patient Experiences of In... |
| [NCT05800210](https://clinicaltrials.gov/study/NCT05800210) | Phase 2 | Recruiting | University of Florid... | Alpha/Beta T Cell and CD19+ B Cell ... |
| [NCT06462365](https://clinicaltrials.gov/study/NCT06462365) | Phase 1 | Recruiting | Tr1X, Inc. | Phase I, First in Human, Open Label... |
| [NCT05959434](https://clinicaltrials.gov/study/NCT05959434) | Phase 2 | Recruiting | Texas A&M University | Integration of Cognitive Processing... |
| [NCT06227026](https://clinicaltrials.gov/study/NCT06227026) | Phase 1 | Recruiting | University of Utah | Pilot Study of Anti-CD19 Chimeric A... |
| [NCT06211413](https://clinicaltrials.gov/study/NCT06211413) | N/A | Enrolling by invitation | Abramson Cancer Cent... | A Prospective Longitudinal Cohort S... |
| [NCT05672251](https://clinicaltrials.gov/study/NCT05672251) | Phase 2 | Recruiting | City of Hope Medical... | A Phase 2 Study of Loncastuximab Te... |
| [NCT06001385](https://clinicaltrials.gov/study/NCT06001385) | Phase 2 | Recruiting | Center for Internati... | A Phase II Study of Reduced Dose Po... |
| [NCT05702645](https://clinicaltrials.gov/study/NCT05702645) | N/A | Recruiting | Children's Oncology ... | Chronic Health Conditions in Down S... |
| [NCT05702853](https://clinicaltrials.gov/study/NCT05702853) | Phase 1/Phase 2 | Recruiting | Medical University o... | A Phase 1b Dose Escalation Study of... |
| [NCT06357754](https://clinicaltrials.gov/study/NCT06357754) | N/A | Recruiting | Bristol-Myers Squibb | Protocol for Transgene Assay Servic... |
| [NCT05947851](https://clinicaltrials.gov/study/NCT05947851) | Phase 3 | Recruiting | Merck Sharp & Dohme ... | A Phase 3, Open-label, Randomized S... |
| [NCT05876923](https://clinicaltrials.gov/study/NCT05876923) | Not Applicable | Recruiting | Mayo Clinic | The Effects of Acute and Chronic Ex... |
| [NCT05753501](https://clinicaltrials.gov/study/NCT05753501) | Phase 1 | Recruiting | AbbVie | First-in-Human Study to Evaluate th... |
| [NCT05650723](https://clinicaltrials.gov/study/NCT05650723) | Phase 2 | Recruiting | Weill Medical Colleg... | Zanubrutinib and Venetoclax as Init... |
| [NCT05643235](https://clinicaltrials.gov/study/NCT05643235) | Not Applicable | Recruiting | Northwell Health | Implanted Loop Recorders (ILR) for ... |
| [NCT05442515](https://clinicaltrials.gov/study/NCT05442515) | Phase 1/Phase 2 | Recruiting | National Cancer Inst... | Phase 1/2 Dose Escalation Study of ... |
| [NCT05170399](https://clinicaltrials.gov/study/NCT05170399) | Phase 4 | Recruiting | National Heart, Lung... | Vaccine Responses in Patients With ... |
| [NCT05254743](https://clinicaltrials.gov/study/NCT05254743) | Phase 3 | Recruiting | Loxo Oncology, Inc. | A Phase 3 Open-Label, Randomized St... |
| [NCT05418088](https://clinicaltrials.gov/study/NCT05418088) | Phase 1 | Recruiting | Sumithira Vasu | Phase I Clinical Trial of Anti-CD19... |
| [NCT04785989](https://clinicaltrials.gov/study/NCT04785989) | N/A | Recruiting | University of Wiscon... | Metabolic Profiling of Leukemic Cel... |
| [NCT05131022](https://clinicaltrials.gov/study/NCT05131022) | Phase 1 | Recruiting | Nurix Therapeutics, ... | A Phase 1, Dose Escalation, and Coh... |
| [NCT05082519](https://clinicaltrials.gov/study/NCT05082519) | Phase 2 | Recruiting | Etan Orgel | A Phase 2 Randomized Trial of Calor... |
| [NCT05006716](https://clinicaltrials.gov/study/NCT05006716) | Phase 1/Phase 2 | Recruiting | BeOne Medicines | A Phase 1/2, Open-Label, Dose-Escal... |
| [NCT04771572](https://clinicaltrials.gov/study/NCT04771572) | Phase 1 | Recruiting | Newave Pharmaceutica... | A Phase 1/1b Study Evaluating the S... |
| [NCT03219450](https://clinicaltrials.gov/study/NCT03219450) | Phase 1 | Recruiting | Dana-Farber Cancer I... | A Pilot Study of a Personalized Neo... |
| [NCT04792489](https://clinicaltrials.gov/study/NCT04792489) | Phase 2 | Recruiting | Miltenyi Biomedicine... | A Multi-center Single Arm Phase II ... |
| [NCT04588922](https://clinicaltrials.gov/study/NCT04588922) | Phase 1/Phase 2 | Recruiting | Sellas Life Sciences... | A Phase I/IIa, Open-Label Dose Esca... |
| [NCT04830137](https://clinicaltrials.gov/study/NCT04830137) | Phase 1 | Recruiting | Nurix Therapeutics, ... | A Phase 1, Dose Escalation, Safety ... |

*... and 15 more trials (see trials.csv for full list)*
